CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
ziprasidone +1 moredrug
Likely dose
ziprasidone 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00635700
NCT00635700Phase 2Completed
CompareCT.gov

Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk

Yale University·interventional·Posted Mar 14, 2008·Updated Mar 27, 2023

In Brief

A Phase 2 clinical trial evaluating ziprasidone and placebo for Psychosis Prodrome. Completed, enrolled 51 participants across 11 sites in 2 countries.

Detailed Summary

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsychosis Prodrome
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 14, 2008
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 18.3 years ago

Interventions

ziprasidonedrug

20-160 mg/d

placebodrug

placebo